AVADEL PHARMACEUTICALS PLC Income Statement
AVDL / Health Care|12 years of annual SEC 10-K data (FY2013-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
AVADEL PHARMACEUTICALS PLC reported $169M in revenue and $49M in net loss for FY2024. Revenue has grown at a 40.0% compound annual rate over the past 11 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.1M | $28.0M | $0 | $0 | $22.3M | $59.2M | $103.3M | $173.2M | $150.2M | $173.0M | $15.0M | $4.2M |
| Cost of Revenue | $15.3M | $846.0K | $0 | $0 | $5.7M | $12.1M | $17.5M | $16.3M | $13.2M | $11.4M | $3.4M | $562.0K |
| Gross Profit | $153.8M | $27.1M | $0 | $0 | - | - | - | - | - | - | - | - |
| SG&A Expense | $181.0M | $151.7M | $74.5M | $68.5M | $32.4M | $30.2M | $100.4M | $58.9M | $44.2M | $21.7M | $15.7M | $13.2M |
| R&D Expense | $15.2M | $13.3M | $20.7M | $17.1M | $20.4M | $32.9M | $39.3M | $33.4M | $34.6M | $25.6M | $17.3M | $16.0M |
| Operating Income | -$42.4M | -$137.8M | -$98.6M | -$85.5M | $5.8M | -$24.1M | -$104.9M | $89.5M | -$5.0M | $70.8M | -$93.7M | -$53.7M |
| Interest Expense | $10.8M | $9.9M | $12.3M | $9.9M | $13.0M | $12.5M | $10.6M | $1.1M | $963.0K | $0 | $5.7M | $2.6M |
| Income Tax | -$247.0K | -$501.0K | $26.0M | -$15.8M | -$12.1M | -$5.4M | -$17.9M | $24.4M | $31.6M | $35.9M | -$644.0K | -$11.2M |
| Net Income | -$48.8M | -$160.3M | -$137.5M | -$77.3M | $7.0M | -$33.2M | -$95.3M | $68.3M | -$41.3M | $41.8M | -$85.5M | -$42.9M |
| EPS (Basic) | -$0.51 | -$2.00 | -$2.29 | -$1.32 | $0.13 | -$0.89 | -$2.55 | $1.69 | -$1.00 | $1.03 | -$2.36 | -$1.69 |
| EPS (Diluted) | -$0.51 | -$2.00 | -$2.29 | -$1.32 | $0.13 | -$0.89 | -$2.55 | $1.63 | -$1.00 | $0.96 | -$2.36 | -$1.69 |
| Shares Outstanding | 95.1M | 80.2M | 60.1M | 58.5M | 54.9M | 37.4M | 37.3M | 41.8M | 41.2M | 43.6M | 36.2M | 25.4M |
| Gross Margin | 91.0% | 97.0% | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | -25.1% | - | - | - | 26.0% | -40.7% | - | 51.7% | -3.3% | 40.9% | - | - |
| Profit Margin | -28.9% | - | - | - | 31.5% | -56.1% | -92.3% | 39.4% | -27.5% | 24.2% | - | - |